
GKOS Earnings
Glaukos Corp
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Glaukos Corp(GKOS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Glaukos Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-07-30 | After Hours | -0.26 | -0.24 | +7.69 | 115.48M | 124.12M | +7.48 | -8.46 | -6.37 |
FY2025Q1 | 2025-04-30 | After Hours | -0.33 | -0.22 | +33.33 | 102.78M | 106.66M | +3.78 | -11.36 | -7.48 |
FY2024Q4 | 2025-02-20 | After Hours | -0.43 | -0.40 | +6.98 | 100.96M | 105.50M | +4.50 | -20.01 | -24.80 |
FY2024Q3 | 2024-11-04 | After Hours | -0.52 | -0.28 | +46.15 | 91.47M | 96.67M | +5.69 | -2.68 | +8.88 |
FY2024Q2 | 2024-07-31 | - | -0.52 | -0.52 | - | 88.90M | 95.69M | +7.64 | -0.61 | -0.98 |
FY2024Q1 | 2024-05-01 | - | -0.58 | -0.70 | -20.69 | 79.66M | 85.62M | +7.48 | +3.03 | +12.48 |
FY2023Q4 | 2024-02-21 | - | -0.56 | -0.63 | -12.50 | 78.53M | 82.37M | +4.88 | +0.72 | -1.80 |
FY2023Q3 | 2023-11-01 | - | -0.56 | -0.50 | +10.71 | 75.27M | 78.05M | +3.70 | +1.80 | -8.65 |
FY2023Q2 | 2023-08-02 | - | -0.57 | -0.55 | +3.51 | 74.66M | 80.40M | +7.68 | -2.58 | -2.50 |
- | 2023-05-03 | - | -0.61 | -0.59 | +3.28 | - | - | - | +2.24 | +26.74 |
GKOS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Glaukos Corp reported performance for FY2025Q2, announced on 2025-07-30. The company achieved an EPS of -0.24, compared to analyst estimates of -0.26 by 7.69% . Revenue for the quarter reached 124.12M compared to expectations of 115.48M by 7.48% .
The stock price reacted with a -8.46% one-day change and a -6.37% five-day change following the earnings release. These movements reflect market reaction in Glaukos Corp growth trajectory and strategic initiatives.
GKOS Earnings Forecast
Looking ahead, Glaukos Corp(GKOS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 122.51M and an EPS of -0.26.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.78%, while EPS estimates have been Revise Upward by 6.85%. For the upcoming Q3 2025, revenue estimates have been adjusted Revise Upward by 1.65% . These revisions correlate with a -0.59% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Glaukos Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between GKOS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+0.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+6.85%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Upward

+1.65%
In Past 3 Month
Stock Price
Go Down

-0.59%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:484.53M
--
EPS Estimate-Annual FY 2025:-0.90
—
Stock Price91.08
GKOS Revenue and EPS Performance: A Historical Perspective
Glaukos Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-07-30,After Hours):
EPS: -0.24 (Actual) vs.-0.26 (Estimate) (7.69%)
Revenue: 124.12M (Actual) vs. 115.48M (Estimate) (7.48%)
Price Reaction: -8.46%(1-Day), -6.37%(5-Day)
FY2025Q1 (2025-04-30,After Hours):
EPS: -0.22 (Actual) vs.-0.33 (Estimate) (33.33%)
Revenue: 106.66M (Actual) vs. 102.78M (Estimate) (3.78%)
Price Reaction: -11.36%(1-Day), -7.48%(5-Day)
FY2024Q4 (2025-02-20,After Hours):
EPS: -0.40 (Actual) vs.-0.43 (Estimate) (6.98%)
Revenue: 105.50M (Actual) vs. 100.96M (Estimate) (4.50%)
Price Reaction: -20.01%(1-Day), -24.80%(5-Day)
Earnings Reaction
The chart below shows how GKOS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GKOS sees a +1.79% change in stock price 10 days leading up to the earnings, and a -0.44% change 10 days following the report. On the earnings day itself, the stock moves by +0.31%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -8.46% on the day following the earnings release and then changed by -2.40% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Glaukos Corp (GKOS) Q2 2025 Earnings Call Summary
Positive
2025-07-31
The earnings call highlighted strong product developments with iDose and Epioxa, positive market strategy with expanded collaborations, and optimistic guidance for iDose revenue. Despite some concerns about reimbursement changes and SG&A expenses, the overall sentiment is positive with raised guidance and strategic market positioning.
Glaukos Corp (GKOS) Q1 2025 Earnings Call Summary
Positive
2025-04-30
The earnings call highlights strong financial performance with a 25% increase in net sales and a robust cash position. While there are challenges like LCD restrictions and potential economic impacts, the company's strategic focus on iDose TR and successful market expansion suggest optimism. The Q&A revealed analysts' concerns about economic exposure and regulatory hurdles, but management's optimistic guidance and strong product adoption mitigate these worries. No share repurchase plan is a neutral factor. Overall, the company's growth outlook and strategic initiatives indicate a positive stock price movement.
Glaukos Corp (GKOS) Q1 2025 Earnings Call Summary
Positive
2025-04-30
The earnings call reveals strong financial performance with a 25% YoY increase in net sales, driven by iDoseTR adoption, and no debt, indicating good financial health. Despite competitive pressures and regulatory issues, the company shows resilience with positive guidance for iDose. The Q&A section highlights management's strategic focus on addressing reimbursement challenges and expanding market access. Although shareholder returns were not addressed, the overall sentiment is positive due to strong financial metrics and optimistic guidance, likely leading to a positive stock price movement over the next two weeks.
Glaukos Corporation (GKOS) Q3 2024 Earnings Call Summary
Positive
2024-11-05
The earnings call summary and Q&A indicate strong financial performance with a 24% YoY increase in net sales, positive market reception of iDose TR, and optimistic guidance for future growth. Despite competitive pressures and macroeconomic challenges, the company is strategically managing debt and capital. The management's confidence in the adoption of iDose TR and upcoming product launches, alongside raised sales guidance, supports a positive sentiment. However, lack of clarity in some responses slightly tempers the outlook. Overall, the sentiment is positive, suggesting a 2% to 8% stock price increase.
Glaukos Corporation (GKOS) Q2 2024 Earnings Call Summary
Positive
2024-08-01
The earnings call summary presents strong financial performance with 19% YoY growth in net sales and 26% growth in US glaucoma sales. The company is also advancing its product pipeline and has secured positive reimbursement developments. While there are risks like competitive pressures and regulatory challenges, the share repurchase program and optimistic guidance for breakeven in 2025 are positive. The Q&A session reveals cautious optimism about iDose adoption, but no major negative sentiment. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
People Also Watch

AOS
A O Smith Corp
72.520
USD
-1.52%

NYT
New York Times Co
60.130
USD
-0.81%

NBIS
Nebius Group NV
68.460
USD
-3.07%

MOS
Mosaic Co
32.100
USD
-0.34%

ENPH
Enphase Energy Inc
32.220
USD
-5.84%

AGNC
AGNC Investment Corp
9.610
USD
-0.52%

LW
Lamb Weston Holdings Inc
54.830
USD
+0.18%

ZION
Zions Bancorporation NA
53.770
USD
-0.17%

BRKR
Bruker Corp
33.640
USD
-2.61%

OGE
OGE Energy Corp
45.670
USD
+0.04%
FAQ

What were the key highlights of GKOS’s latest earnings report for FY2025Q2?
GKOS reported its FY2025Q2 earnings on 2025-07-30, showcasing a revenue of 124.12M against an estimate of 115.48M, resulting in a 7.48% surprise. The EPS was -0.24, surpassing the expected -0.26 by 7.69% . The stock experienced a -8.46% price change on the earnings day and a -6.37% change over the next five days, reflecting market reactions to the results.

How did GKOS’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for GKOS for 2025/Q3?

How does GKOS’s stock price correlate with earnings forecast revisions?

What should investors expect from GKOS’s next earnings report?
